Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T15785 |
LPA1 receptor antagonist 1
LPA1 R antagonist 1 |
LPA Receptor | GPCR/G Protein |
LPA1 receptor antagonist 1(LPA1 R antagonist 1) 是一种具有选择性和高效性的溶血磷脂酸 (LPA1) 受体拮抗剂( IC50 : 25 nM),可用于研究特发性肺纤维化。 | |||
T7393 |
ONO-7300243
|
LPA Receptor; LPL Receptor | GPCR/G Protein |
ONO-7300243 是溶血磷脂酸受体 1 (LPA1)拮抗剂,IC50为 0.16 μM。 | |||
T7689 |
Tetradecyl Phosphonate
|
LPA Receptor | GPCR/G Protein |
Tetradecyl Phosphonate 是溶血磷脂酸 1 (LPA1)、LPA2 和 LPA3 受体的泛拮抗剂。 | |||
T39647 |
BMS-986278
|
LPA Receptor | GPCR/G Protein |
BMS-986278 是一种具有口服活性和高效性的血磷脂酸受体 1 (LPA1) 拮抗剂,对人和小鼠 LPA1 的 Kb 值分别为 6.9 nM 和 4.0 nM。BMS-986278 可用于研究用于特发性肺纤维化。 | |||
T4016 |
BMS-986020
AM152,BMS986020 |
LPA Receptor; LPL Receptor | GPCR/G Protein |
BMS-986020 (AM152) 是一种高亲和力溶血磷脂酸受体 1 拮抗剂,有用于特发性肺纤维化的研究潜力。它抑制胆汁酸和磷脂转运蛋白,抑制 BSEP、MRP4 和 MDR3,IC50值分别为 4.8、6.2 和 7.5 μM。 | |||
T14335 | ASP6432 | LPA Receptor | GPCR/G Protein |
ASP6432 is an antagonist of type 1 lysophosphatidic acid receptor (LPA1). For human LPA1 and rat LPA1, the IC50s are 11 nM and 30 nM , respectively. | |||
T63645 |
ONO-9780307
|
||
ONO-9780307 是 LPA1 (lysophosphatidic acid receptor 1) 的特异性拮抗剂 (IC50: 2.7 nM)。 | |||
T29109 |
VPC12249
VPC-12249,VPC 12249 |
||
VPC12249, a lysophosphatidic acid receptor type 1 (LPA1) antagonist, plays a functional role in osteoclast differentiation and bone resorption activity. | |||
T28245 |
ONO-0300302
ONO 0300302 |
||
ONO-0300302 is a slow tight binding LPA1 antagonist (IC50: 0.16 nM) used to treat Benign Prostatic Hyperplasia. ONO-0300302 inhibits significantly an LPA-induced increase of intraurethral pressure (IUP) in rat (3 mg/kg, p.o.) and dog (1 mg/kg, p.o.) over | |||
T63439 | BMS-986020 sodium | ||
BMS-986020 sodium 是高亲和力的溶血磷脂酸受体 1 (LPA1) 拮抗剂,能够抑制胆汁酸和磷脂转运蛋白,并抑制 BSEP (IC50: 4.8 μM),MRP4 (IC50: 6.2 μM) 和 MDR3 (IC50: 7.5 μM)。BMS-986020 sodium 表现出特发性肺纤维化 (IPF) 的研究潜力。 |